FDA Approves Riabni, 3rd Rituxan Biosimilar to Treat GPA and MPA

FDA Approves Riabni, 3rd Rituxan Biosimilar to Treat GPA and MPA

282399

FDA Approves Riabni, 3rd Rituxan Biosimilar to Treat GPA and MPA

The U.S. Food and Drug Administration (FDA) has approved Amgen‘s Riabni (rituximab-arrx), a biosimilar to Rituxan (rituximab), to treat adults with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the two most common subtypes of ANCA-associated vasculitis. The FDA also approved Riabni to treat two blood cancers, non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. The company plans to make the therapy available in the U.S. before the close of January. Riabni is now the third biosimilar to Rituxan to be approved in the U.S.…

You must be logged in to read/download the full post.